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ABSTRACT
The lncRNA HOTAIR has been implicated in several human cancers. Here, we 
evaluated the molecular alterations and upstream regulatory mechanisms of HOTAIR 
in glioma, the most common primary brain tumors, and its clinical relevance. HOTAIR 
gene expression, methylation, copy-number and prognostic value were investigated 
in human gliomas integrating data from online datasets and our cohorts. High levels 
of HOTAIR were associated with higher grades of glioma, particularly IDH wild-type 
cases. Mechanistically, HOTAIR was overexpressed in a gene dosage-independent 
manner, while DNA methylation levels of particular CpGs in HOTAIR locus were 
associated with HOTAIR expression levels in GBM clinical specimens and cell lines. 
Concordantly, the demethylating agent 5-Aza-2′-deoxycytidine affected HOTAIR 
transcriptional levels in a cell line-dependent manner. Importantly, HOTAIR was 
frequently co-expressed with HOXA9 in high-grade gliomas from TCGA, Oncomine, 
and our Portuguese and French datasets. Integrated in silico analyses, chromatin 
immunoprecipitation, and qPCR data showed that HOXA9 binds directly to the 
promoter of HOTAIR. Clinically, GBM patients with high HOTAIR expression had a 
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significantly reduced overall survival, independently of other prognostic variables. 
In summary, this work reveals HOXA9 as a novel direct regulator of HOTAIR, and 
establishes HOTAIR as an independent prognostic marker, providing new therapeutic 
opportunities to treat this highly aggressive cancer.
INTRODUCTION
Gliomas encompass the majority of primary central 
nervous system tumors, and have been historically 
classified based on their histopathological features, 
according to four grades of malignancy (World Health 
Organization – WHO – grade I-IV). Glioblastoma 
(GBM; WHO grade IV) represents the most common 
and malignant primary adult brain tumor [1], with a 
median patient overall survival (OS) of approximately 15 
months [2]. The remarkable tumor heterogeneity, invasive 
phenotype, and resistance to radio- and chemotherapy 
are main determinants of this poor prognosis [3–5]. 
Additionally, several molecular alterations (epigenetic, 
genetic, transcriptional and proteomic) contribute to GBM 
tumorigenesis and may represent putative biomarkers of 
GBM prognosis and aggressiveness [6].
Recent studies have explored the complexity of 
the transcriptome and reported the existence of a large 
number of transcripts that do not code for a protein, 
which nonetheless have the critical ability to regulate 
gene expression [7]. Among others, these transcripts 
include long non-coding RNAs (lncRNA) [8, 9] that are 
defined as spliced, polyadenylated and >200 nucleotides 
long RNAs that modify the genome in a highly tissue-
specific manner [9, 10]. LncRNA have also emerged 
as new players in cancer development and progression, 
with recent studies highlighting the importance of 
both tumor suppressor and oncogenic lncRNAs in the 
deregulation of cellular pathways and gene expression 
programs [11]. The HOX Transcript Antisense Intergenic 
RNA (HOTAIR) is a trans-acting lncRNA, involved 
in the genome-wide reprogramming of the chromatin 
[10]. HOTAIR is transcribed at the HOXC locus in 
chromosome 12 (between HOXC11 and HOXC12), and 
its 5′-domain interacts with the Polycomb Repressor 
Complex 2 (PRC2), and the 3′-domain interacts with the 
lysine specific demethylase 1/REST corepressor 1/RE1-
silencing transcription factor (LSD1/CoREST/REST) 
complex. Thus, HOTAIR can act as modular scaffold, with 
different binding sites for harboring demethylase (LSD1, 
that mediates the enzymatic demethylation of histone H3 
dimethyl lysine 4, H3K4me2) and methylase (PRC2 and 
the histone H3 lysine 27 – H3K27 – methylase EZH2) 
complexes, resulting in the transcriptional inhibition of the 
HOXD locus on chromosome 2 by epigenetic control of 
the chromatin structure [10, 12]. 
HOTAIR has also been shown to have functional 
roles in a variety of human cancers (reviewed in [13–15]), 
being associated with patients’ decreased OS, increased 
metastatic potential, tumor recurrence and chemotherapy 
resistance. In glioma, HOTAIR was reported to be involved 
in proliferation, invasion, cell cycle and colony formation 
ability, in vivo tumor growth, and GBM patients’ OS 
[16–20]. However, the molecular mechanisms underlying 
its aberrant activation in glioma remain elusive. In this 
context, we aimed to investigate the integrated molecular 
status (gene copy number, expression, and DNA 
methylation levels) of HOTAIR in glioma samples, unravel 
the underlying mechanisms regulating HOTAIR expression 
in these tumors, and assess its clinical significance in 
independent large cohorts of GBM.
RESULTS
HOTAIR expression is associated with high-
grade gliomas
In a first approach, we analyzed the expression 
levels of HOTAIR in grades II and III gliomas, and in 
grade IV GBM patients using gene expression microarray 
data and RNA-sequencing (RNA-seq) data from The 
Cancer Genome Atlas (TCGA). Globally, HOTAIR was 
highly expressed in GBM, particularly in IDH-wt GBM, 
as compared to lower-grade gliomas and normal brain 
(Figure 1A and Supplementary Figure 1A). Of note, in 
the RNA-seq data, IDH-wt grade III gliomas presented 
higher HOTAIR expression than the remaining grade 
II and III gliomas entities (Supplementary Figure 1A). 
Concordantly, four additional datasets from the Oncomine 
database (Murat [21], Freije [22], Sun [23], and Phillips 
[24]) and two independent Portuguese and French glioma 
series, confirmed that HOTAIR expression is far more 
frequent in grades III and IV than in grade II gliomas and 
normal brain (Supplementary Table 1 and Supplementary 
Figure 1B). In all tested glioma datasets, HOTAIR 
expression was not significantly associated with any other 
clinicopathological feature (patient age, sex, Karnofsky 
performance status [KPS], and exposure to radiotherapy 
or chemotherapy, except for associations with patient 
age in Phillips [24], Repository of Molecular Brain 
Neoplasia Data (REMBRANDT) and the French datasets, 
and associations with IDH mutation status in the French 
datatset; data not shown). Moreover, HOTAIR expression 
was not associated with any particular GBM molecular 
subtype as defined by Wang et al. [25] (Supplementary 
Figure 1C and 1D; p > 0.9999 for microarray and RNA-
seq data). Together, these data suggest that HOTAIR is 
highly expressed in high-grade gliomas, being particularly 
frequent in IDH-wt cases.
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DNA methylation regulates HOTAIR levels in 
glioma
In order to understand the molecular mechanisms 
underlying HOTAIR increased expression in GBMs, we 
analyzed gene copy number aberrations (Figure 1B) and 
DNA methylation levels in the HOTAIR locus (Figure 1C). 
In 250 IDH-wt GBMs analyzed for gene copy number, 
HOTAIR amplification and deletion (either focal or 
chromosomal) were found in 0.8% (2/250) and in 3.2% 
of the samples (8/250; Figure 1B), respectively, while 
no amplifications or deletions were found in 20 IDH-
mut GBMs (Figure 1B). While HOTAIR levels were 
high in 3 of the 5 HOTAIR-amplified tumors, it was also 
present in 1 tumor with gene deletion and in 116 without 
copy number aberrations (Figure 1B). These data show 
HOTAIR copy number aberrations are rare in GBM, and 
unlikely associated with its increased expression levels 
(p = 0.182). Analysis of 56 methylation probes spanning 
from HOTAIR’s most proximal genes (HOXC11 and 
(HOXC12) revealed a wide spectrum of methylation levels 
across different GBM samples (Figure 1C). Of note, some 
probes consistently presented similar methylation levels 
across all samples (e.g., several probes within the HOTAIR 
intragenic region consistently showed low methylation 
levels), suggesting those regions are not prone to de novo 
methylation in GBM. In a subset of 70 GBMs (66 IDH-
wt and 4 IDH-mut) for which both gene expression and 
methylation data were available, we found the methylation 
levels of 3 probes located in the intragenic region of 
HOTAIR (cg00079219, cg18824990 and cg24895871) 
to be significantly inversely correlated with HOTAIR 
expression levels (r = –0.36, p = 0.002; r = –0.43, p = 
0.0002; and r = –0.35, p = 0.003, respectively; Figure 
1D). Of note, performing the same analysis exclusively 
for the IDH-wt GBMs showed that the methylation levels 
of the probes cg00079219 and cg18824990 were inversely 
correlated with HOTAIR expression (r = –0.39, p = 0.0002; 
r = –0.39, p = 0.0014), while methylation levels at the 
probe cg24895871 lost their association with expression (r 
= –0.26, p = 0.167). We further corroborated the relevance 
of these associations in IDH-wt GBM patients in the 
French dataset as the 3 intragenic methylation probes were 
also found to inversely correlate with HOTAIR expression 
(cg00079219 r = –0.53, p = 0.016; cg18824990 r = 
–0.523, p = 0.017; cg24895871 r = –0.521, p = 0.018), 
and in the combination of IDH-wt glioma grade III and 
IDH-wt GBM patients (cg00079219 r = -0.43, p = 0.004; 
cg18824990 r = –0.453, p = 0.002; cg24895871 r = 
−0.431, p = 0.004). 
To further explore the relevance of DNA 
methylation in HOTAIR regulation, we treated glioma cell 
lines with the global DNA demethylating agent 5-Aza-2′-
deoxycytidine (5-Aza) followed by methylation-specific 
PCR (MSP) and quantitative PCR (qPCR) analyses 
(Figure 1E and 1F). Interestingly, HOTAIR intragenic 
CpGs were found to be mostly methylated in untreated 
glioma cells. In addition, 5-Aza treatment resulted in 
DNA demethylation (Figure 1E) and associated increase 
in HOTAIR transcriptional levels in most but not all of 
the cell lines (Figure 1F), suggesting a cell line-dependent 
regulation. Together, our data suggest an association 
between methylation and HOTAIR’s expression in GBM 
patients and glioma cell lines, but other mechanisms may 
be crucial in reactivating HOTAIR in these tumors.
HOXA9 directly binds the HOTAIR promoter in 
GBM cells
Previously published transcriptomic data from 
our group (GEO accession number GSE56517) [26, 
27] suggested a possible regulation of HOTAIR by the 
homeoprotein HOXA9, an important protein in the 
aggressiveness, chemotherapy resistance, and prognosis 
of GBM [21, 26, 28, 29]. Specifically, GBM cell lines 
with overexpression or silencing of HOXA9 presented 
increased or reduced expression of HOTAIR, respectively; 
raising the hypothesis that HOXA9 may directly regulate 
HOTAIR expression. Indeed, an in silico analysis 
using MatInspector (Genomatix) revealed 3 putative 
binding sites for HOXA9 with high matrix similarities 
to HOXA9.02 (0.899), PBX-HOXA9.01 (0.849), and 
MEIS1B-HOXA9.01 (0.837) matrixes (Figure 2A), 
suggesting that HOXA9 may bind to the promoter 
region of HOTAIR and regulate its transcription. To test 
this, we studied the expression pattern of HOTAIR and 
HOXA9 in adult and pediatric glioma-derived cell lines 
by semi-quantitative reverse transcription-PCR (RT-
PCR) and qPCR, and found these genes to be frequently 
co-expressed in glioma (Figure 2B and 2C). Moreover, 
U87MG-HOXA9 cells (with exogenous overexpression 
of HOXA9) presented significantly increased expression 
of HOTAIR as compared to their HOXA9-negative 
counterpart (U87MG-MSCV; Figure 2B and 2C). We then 
performed anti-HOXA9 chromatin-immunoprecipitation 
(ChIP) on U251 GBM cell line (endogenously expressing 
HOTAIR and HOXA9), U87MG-HOXA9 (HOXA9 
overexpression models) and their HOXA9-negative 
counterparts. In both U251 and U87MG-HOXA9, ChIP-
qPCR revealed significantly increased HOXA9 occupancy 
of the promoter region of HOTAIR in comparison to their 
respective controls (Figure 2D and 2E; p < 0.0002 for 
U251; p = 0.0148 for U87MG-HOXA9), confirming that 
HOXA9 directly interacts with the promoter region of 
HOTAIR. Together, these results indicate that HOXA9 is 
a direct activator of HOTAIR expression in GBM cells, 
thus supporting the strong co-expression of these genes 
observed in glioma cell lines. 
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Co-expression of HOTAIR and HOXA9 is a 
frequent event in clinical specimens of glioma
To verify if the frequent co-expression of HOTAIR 
and HOXA9 in glioma cell lines is present in glioma 
clinical specimens, we evaluated their expression levels 
and potential correlations in the Portuguese, French, and 
TCGA datasets. We found that HOTAIR and HOXA9 
frequently have a coherent transcriptional activation 
status in grade IV glioma (Portuguese dataset Pearson’s 
r = 0.642, p < 0.0001; IDH-wt GBM in French dataset 
Pearson’s r = 0.649, p = 0.002; IDH-wt GBM in TCGA 
microarray dataset Pearson’s r = 0.494, p < 0.0001; IDH-
wt GBM in TCGA RNA-seq dataset Pearson’s r = 0.525, 
p < 0.0001; Figure 3A–3C, Supplementary Figure 2H 
and Table 1). Similarly, significant correlations between 
HOTAIR and HOXA9 expression were also observed 
in specific combinations of glioma grades (Portuguese 
dataset WHO grades II+III, III, III+IV and II+III+IV; 
French dataset IDH-wt WHO grade III and grade IV; Table 
1 and Supplementary Figure 2A–2G). While HOTAIR and 
HOXA9 co-expression did not reach statistical significance 
for grade II gliomas (n = 6; Supplementary Figure 2A), this 
is likely due to the small sample size, and the same trend 
for co-expression was observed; indeed, all of these tumors 
were either double-positive or double-negative (Table 1). 
Further analysis in 4 independent datasets showed a 
statistically significant correlation between the expression 
of HOTAIR and HOXA9 in all glioma sets (Table 2). 
Furthermore, in IDH-wt (n = 55) and IDH-mut (n = 137) 
grades II and III glioma with available RNA-seq data from 
TCGA, a statistically significant correlation between the 
expression of HOTAIR and HOXA9 was also found (IDH-
wt Spearman’s r = 0.65, p < 0.0001, and IDH-mut r = 
0.21, p = 0.01; data not shown), while in 1p19q codeleted 
and IDH-mut grades II and III glioma no correlation 
was found (n = 85, r < 0.01, p = 0.999; data not shown). 
Interestingly, no significant correlations between HOTAIR 
and HOXA9 were found for other cancer types, including 
lung, leukemia, colorectal, and breast cancers (Table 2). 
Taken together, our results strongly suggest that HOTAIR 
and HOXA9 are concomitantly co-expressed in human 
gliomas, but not in other cancer types.
High levels of HOTAIR expression associate 
with shorter survival in patients with malignant 
glioma
To validate the prognostic value of HOTAIR 
expression reported in GBM patients from the Chinese 
population [16], we firstly analyzed two independent 
datasets of GBM patients from TCGA and REMBRANDT. 
In 554 GBM patients from TCGA with available survival 
data, a statistically significant decrease in OS was observed 
in patients with high HOTAIR expression (n = 177, median 
OS = 383 days) as compared to patients whose GBMs 
presented low HOTAIR levels (n = 377, median OS = 
447 days; p = 0.026 Log-rank test; Figure 4A). Similarly, 
associations were found in the subset of 387 IDH-wt 
GBMs (HOTAIR-high n = 126, median OS = 370 days and 
HOTAIR-low n = 241, median OS = 447 days; p = 0.032 
Log-rank test; Figure 4B and Supplementary Table 2). As 
expected, classic prognostic factors including patient age 
at diagnosis, KPS, and use of radio-chemotherapy, were 
significantly associated with OS (p < 0.05, Log-rank test, 
Supplementary Table 2). Importantly, HOTAIR expression 
was significantly associated with shorter OS of IDH-wt 
GBM patients in a multivariable Cox model (p = 0.036), 
independently of other prognostic factors (age, gender, 
KPS, use of chemoradiotherapy, and treatment with 
additional chemoradiotherapy; Supplementary Table 2). 
Consistently, in an independent dataset of 67 GBM 
patients from the REMBRANDT dataset, high HOTAIR 
expression was present in 72% of patients (n = 48) who 
Figure 1: Molecular characterization of HOTAIR in gliomas. (A) Expression levels of HOTAIR in 424 gliomas, stratified 
according to WHO grade, IDH and 1p/19q codeletion statuses (1 IDH-wt, 3 IDH-mut, and 3 IDH-mut and 1p/19q codeleted grade II 
gliomas; 1 IDH-wt, 12 IDH-mut, and 6 IDH-mut and 1p/19q codeleted grade III gliomas; 368 IDH-wt and 30 IDH-mut glioblastomas 
(GBM); and 10 unmatched normal brains from the TCGA microarray data). HOTAIR is highly expressed (TCGA data “level 3” values ≥ 0) 
in 34.2% (n = 126) of IDH-wt GBM samples and in 1 IDH-mut GBM (3%) and 1 IDH-wt grade II glioma (100%). (B) HOTAIR gene copy 
number status in 270 GBMs (250 IDH-wt and 20 IDH-mut) from TCGA. HOTAIR is amplified (Log2 Copy Number Tumor/Normal ≥ 0.5) 
in 0.8% (n = 2; green dots), and deleted (Log2 Copy Number Tumor/Normal ≤ –0.5) in 3.2% (n = 8; red dots) of IDH-wt GBM samples. 
Red dashed lines represent the normal copy number interval. (C) Heatmap representations of DNA methylation levels (TCGA β-values) of 
the chromosomal region encompassing HOTAIR and the 2 closest genes (HOXC12 and HOXC11) in 74 GBMs (70 IDH-wt and 4 IDH-mut) 
from TCGA. A total of 56 methylation probes (vertical blue bars) were assessed. CpG islands > 300bp are represented in green. *indicate 
probes whose methylation indexes are significantly inversely correlated with HOTAIR expression levels (probes cg00079219, cg18824990 
and cg24895871). The color code (grades of red color corresponding to different methylation indexes) is shown below the heatmap. Each 
column corresponds to a probe and each row to a patient. (D) Correlation graphs between HOTAIR expression levels (TCGA “level 3” 
value) and DNA methylation indexes (TCGA β-values) in 70 GBM samples. Only probes whose methylation values are significantly 
inversely correlated with HOTAIR expression are shown (cg00079219, cg18824990 and cg24895871; marked with *in C). (E–F) Glioma 
cell lines were treated with 5 µM 5-Aza for 72 hours, upon which promoter methylation status (E) and HOTAIR expression levels (F) were 
evaluated. 5-Aza treatment promoted HOTAIR promoter demethylation (E) that associated with its increased expression in a cell line-
dependent manner (F). qPCR levels were normalized to the expression of HPRT1 and are presented as fold-changes; methylation-specific 
PCR was controlled by blood DNA (NB) untreated (Control) or in vitro methylated (Met). No detectable HOTAIR expression was found 
for U87 (untreated or 5-Aza-treated). The results are representative of at least 2 replicates (mean ± SD). *p < 0.05; NB - DNA from normal 
blood.
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Figure 2: HOXA9 transcriptionally activates HOTAIR via direct interaction with its promoter region. (A) MatInspector 
representation of specific binding sites for HOXA9 matrix in HOTAIR promoter region. Each matrix match is represented by a half 
round symbol and each color symbolizes a matrix family. Pink, blue and violet colors represent the matrixes HOXA9.02 (matrix sim 
= 0.899, sequence: ctgtgacaTAAAattgg and family ABDB), PBX-HOXA9.01 (matrix sim = 0.849, sequence: gaggTGGTttatgagct and 
family HOXC) and MEIS1B-HOXA9.01 (matrix sim = 0.837, sequence: TGCCaattttatgtc and family HOXH), respectively. Basepairs 
in italic appear in a position with a high conservation profile in the matrix (ci-value > 60). Basepairs in capital letters represent the core 
sequence used by the program. Matches represented on the top of the sequence line were found on the positive strand, while below the 
sequence line reside matches found on the negative strand. The red arrows represent HOTAIR putative transcription start sites (TSS). 
(B–C) HOTAIR and HOXA9 expression were evaluated by reverse-transcriptase PCR (B) and quantitative PCR (C) in a panel of adult 
and pediatric glioma-derived cell lines, and in the GBM-L18 primary GBM-derived cell culture. GBM cell line U87MG-MSCV does 
not present detectable levels of endogenous HOTAIR expression, which were significantly increased upon retrovirally-mediated HOXA9 
overexpression (U87MG-HOXA9). White and grey bars represent HOTAIR and HOXA9 expressions, respectively. qPCR levels were 
normalized to the expression of HPRT1. The results are representative of triplicates (mean ± SD). *p = 0.029; **p = 0.0088. (D–E) The 
putative binding of HOXA9 protein to the promoter region of HOTAIR was assessed by chromatin immunoprecipitation (ChIP) analysis 
followed by quantitative PCR in U251 cells (D), and U87MG-HOXA9 and their HOXA9-negative counterparts (E). IgG was used as 
negative control for the ChIP. Chromatin immunoprecipitated with an anti-HOXA9 antibody shows direct binding of HOXA9 to the 
HOTAIR promoter. Relative enrichment is normalized to input DNA (not subjected to immunoprecipitation) and to the IgG background 
signal (D), whereas fold change occupancy is normalized to input, IgG and HOXA9-negative cells (E), from three independent experiments 
(mean ± SD). (D) ***p = 0.0002; (E) *p = 0.0148.
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had a significantly shorter OS (median OS = 15.8 months) 
than those with low expression (median OS = 37.4 
months), both in univariable and multivariable analyses (p 
= 0.005 Log-rank test; p = 0.034 Cox regression, Figure 4C 
and Supplementary Table 3). Since HOXA9 expression is 
a known prognostic factor in GBM patients [26, 28, 29], 
we investigated in the large TCGA dataset whether 
HOTAIR was still prognostically valuable in the subset 
of HOXA9-negative IDH-wt GBM patients. Indeed, high 
expression of HOTAIR was able to identify a subgroup 
of HOXA9-negative IDH-wt GBM patients that presented 
a significantly shorter OS (median OS = 375 days) than 
those with low HOTAIR levels (median OS = 463 days; 
Supplementary Figure 3; Log-rank p = 0.037). 
Additionally, we tested the prognostic value of 
HOTAIR expression among 28 glioma grade III patients 
from the French dataset with available survival data. 
Similarly to GBM, we found for the first time an association 
between high HOTAIR expression levels and shorter OS in 
grade III glioma patients with high HOTAIR expression (p = 
0.002, Log-rank test; Supplementary Table 4). Multivariable 
Cox analysis further showed that high HOTAIR expression 
is a poor prognostic factor (p = 0.022) independently of 
other known prognostic factors such as age at diagnosis, 
surgery (partial or complete resection), KPS, treatment, 
and IDH and 1p19q status. The median survival is 1.4 
years [0.7–2.5] in the group of 28 grades III. Survival 
medians are respectively of 2 years in the group of patients 
with HOTAIR-lower expression (n = 16, median HOTAIR 
expression = 0.0002 [2.96e-6 – 0.0053]) and of 0.7 years in 
the group of patients with HOTAIR-higher expression (n = 
12, median HOTAIR expression = 0.0387 [6.4e-6 – 0.0332]).
Finally, we found that high HOTAIR expression is 
also associated with shorter overall survival in grade II 
Figure 3: Expression levels of HOTAIR and HOXA9 are significantly correlated in GBM clinical specimens. (A–C) 
Correlation graphs of HOTAIR and HOXA9 expression levels in GBMs from the Portuguese dataset (A), and IDH-wt GBMs from the 
French dataset (B), and IDH-wt GBMs the TCGA dataset (microarray data) (C), showing statistically significant correlations between their 
expressions in all datasets. (A) Pearson’s r = 0.655, p < 0.0001; (B) Pearson’s r = 0.649; p = 0.002; (C) Pearson’s r = 0.494; p < 0.0001.
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(n = 226) and grade III (n = 240) glioma patients 
in the RNA-seq data from the larger TCGA dataset 
(Supplementary Tables 5 and 6; p = 0.020 and p < 0.0001, 
respectively; Log-rank test), and independently of patient 
age, gender, and molecular subtype (IDH and 1p/19q 
status) in the case of grade II gliomas (p = 0.032; Cox 
regression model), but not for grade III gliomas (p = 0.395; 
Cox regression model), in which high HOTAIR levels were 
highly correlated with wild-type IDH.
Taken together, our findings establish HOTAIR as 
a clinically-relevant biomarker of prognosis in malignant 
glioma patients.
DISCUSSION
An increasing focus has been given to lncRNAs as 
key regulators of a range of biological functions and as 
crucial players in the etiology of disease, especially in 
Table 1: Analysis of HOTAIR and HOXA9 expression correlations in human glioma samples from the Portuguese 
dataset
Grade II Grade III Grade IV
HOTAIR HOTAIR HOTAIR
+ − + − + −
HOXA9
+ 1 0 4 4 8 6
− 0 5 1 5 5 34
r = 0.774
p = 0.07
r = 0.546
p = 0.030
r = 0.655
p < 0.0001
r = 0.619
p = 0.005
r = 0.640
p < 0.0001
r = 0.642
p < 0.0001
*Pearson’s correlation.
Table 2: Analysis of HOTAIR co-expression with HOXA9 in glioma datasets and in other cancer types (lung, leukemia, 
colorectal, and breast cancer datasets from TCGA) available at Oncomine(1)
Datasets Correlation HOTAIR/HOXA9 p-value
Glioma, NOS
Portuguese dataset 0.642 <0.0001
French dataset 0.516 <0.001
TCGA, microarray data 0.545 <0.0001
TCGA, RNA-seq data 0.675 <0.0001
    Oncomine:
 Freije et al. (Freije, et al. 2004) 0.372 <0.001
 Murat (Murat, et al. 2008) 0.293 0.008
 Sun (Sun, et al. 2006) 0.487 <0.0001
 Phillips (Phillips, et al. 2006) 0.309 0.001
Other cancers from Oncomine:
 TCGA Lung 0.046 0.555
 TCGA Leukemia –0.019 0.791
 TCGA Colorectal 0.012 0.854
 TCGA Breast –0.051 0.215
(1)Microarray data from Oncomine dataset, microarray or RNA-seq data from TCGA dataset, quantitative PCR data from 
the Portuguese dataset (relative gene expression normalized to hGUS or TBP levels), and microfluidic-based qPCR analysis 
(Fluidigm) data from the French dataset were used to evaluate the Pearson’s correlation.
NOS – not otherwise specified.
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Figure 4: High levels of HOTAIR expression are significantly associated with shorter survival in GBM patients. Kaplan–
Meier overall survival curves of HOTAIR prognostic value in (A) 554 GBM patients from TCGA, (B) 367 IDH-wt GBM patients from 
TCGA and (C) 67 GBM patients from REMBRANDT dataset, showing patients whose tumors present high HOTAIR expression have a 
statistically significant shorter overall survival compared to those with HOTAIR-low tumors, in both independent datasets (A, p = 0.026; B, 
p = 0.032; C, p = 0.005; Log-rank tests).
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cancer [8, 9]. The relevance of HOTAIR in cancer was first 
reported by an association between HOTAIR expression 
and increased metastatic potential and diminished survival 
of breast cancer patients [30]. Later studies evaluated the 
roles of HOTAIR in several tumor types (reviewed in [13–
15]), globally highlighting oncogenic roles of HOTAIR. 
Likewise, HOTAIR expression was associated with more 
aggressive disease in glioma patients [16–19]. While 
some oncogenic functions of HOTAIR have been reported 
in glioma [17, 31, 32], the underlying mechanisms 
responsible for HOTAIR activation in such a devastating 
disease have remained unknown thus far. Here, we explore 
the multi-layered complexity of HOTAIR activation by 
integrating molecular (genetic and epigenetic) analyses, in 
silico approaches, and data from glioma patients and cell 
lines. Additionally, we further investigated the relevance 
of HOTAIR as a prognostic biomarker in GBM, and in 
malignant WHO grade II and III glioma.
We show that HOTAIR is overexpressed in a subset 
of high-grade gliomas, particularly in GBMs. Of note, our 
study includes data from independent patient datasets, 
and obtained with different complementary techniques, 
including qPCR, expression microarrays, microfluidic-
based qPCR analysis (Fluidigm) and RNA-Seq data. 
To understand the molecular mechanisms regulating 
the expression of HOTAIR, we evaluated copy number 
aberrations and DNA methylation levels, and searched 
for putative transcription factors with binding sites in 
HOTAIR’s promoter region. Copy number alterations 
in HOTAIR locus were rare and did not associate with 
its expression levels, suggesting this is not a prominent 
underlying mechanism in GBM. Contrarily, modulation 
of DNA methylation levels in GBM cell lines by the 
demethylating agent 5-Aza indicated that intragenic 
CpGs in HOTAIR locus affected its transcriptional 
levels in a cell line-dependent manner (globally, most 
cell lines increased HOTAIR levels upon demethylation, 
while U87MG did not, possibly attributable to different 
kinetics of 5-Aza response and/or lack of expression 
of all necessary HOTAIR transcriptional regulators). 
Moreover, methylation probes covering CpG islands in 
HOTAIR locus showed significant inverse correlations 
between HOTAIR’s intragenic DNA methylation and 
expression levels in GBM specimens. In fact, it was 
previously shown that intragenic DNA methylation is 
associated with decreased gene expression by altering the 
chromatin structure and reducing the efficiency of RNA 
Pol II elongation [33, 34]. Although these results indicate 
that DNA methylation may regulate HOTAIR expression 
in GBM, this association was not universal, so other 
transcriptional regulation mechanisms are involved in 
glioma. Previous observations from our group suggested 
HOXA9 as a possible regulator of HOTAIR in glioma 
[26]. HOXA9 is an oncogenic transcription factor whose 
expression was described in a subset of highly aggressive 
GBMs, and associated with patients’ decreased OS [26, 
28]. Interestingly, we found HOTAIR and HOXA9 are 
frequently co-expressed in gliomas, but this was not 
observed in patients with lung, leukemia, colorectal, and 
breast cancers, suggesting that this co-expression may 
be an exclusive event of gliomas. Indeed, our ChIP data 
indicates a direct regulation of HOTAIR by HOXA9, 
which binds to HOTAIR promoter region to activate its 
transcription. While HOXA9 and other HOX genes have 
been shown to be transcriptionally regulated by HOTAIR 
[10, 35] in fibroblasts and breast cancer cell lines, it 
is currently unknown whether a similar regulation of 
HOXA9 may also occur in glioma. Indeed, the expression 
of HOXA9 in GBM is known to be epigenetically 
regulated by the PI3K pathway via inhibition of EZH2-
mediated H3K27 trimethylation at the HOXA9 locus [36], 
and HOTAIR is known to interact with PRC2 complex 
(containing EZH2 and other subunits) to guide it to target 
loci [10, 13, 37]. Therefore, it is conceptually feasible 
that HOTAIR might regulate HOXA9 expression, which 
together with other transcription factors can regulate the 
expression of HOTAIR, in a putative loop mechanism. 
Of note, the roles of HOXA9 in glioma and in breast 
cancer are very distinct: while in the first it displays a 
variety of oncogenic functions, associated with tumor 
aggressiveness, higher grades of malignancy, tumor 
implantation in in vivo models, therapy resistance and 
shorter survival of patients [26, 38–40], in breast cancer 
HOXA9 is a tumor suppressor gene whose expression 
is frequently lost, leading to cell growth, survival, 
invasiveness and changes in morphogenesis [41]. These 
studies highlight the importance of cell context for the 
biological effects mediated by HOXA9, which do not 
thus preclude the possibility that the transcriptional 
regulatory mechanisms between HOTAIR and HOXA9 
may also be distinct in glioma and breast cancer. 
Although conceptually possible, this hypothesis has not 
been tested in GBM, and warrants further elucidation 
in new studies. We report here for the first time the 
ability of HOXA9, a homeoprotein, to directly regulate 
the expression of HOTAIR. While we provide strong 
indications that HOTAIR-positive GBMs may result 
from altered intragenic DNA methylation levels and/or 
HOXA9 binding, other mechanisms cannot be excluded. 
For example, the CT variant of the functional single 
nucleotide polymorphism rs12826786 in HOTAIR locus 
was associated with its higher intratumoral expression 
in glioma [42], and would require further addressing. 
Thus, our work provides novel insights on HOTAIR’s 
transcriptional regulators, widening our understanding 
of the HOTAIR-associated mechanisms of aggressiveness 
and malignancy in gliomas. Interpreting our findings 
at the light of other studies further supports the classic 
tissue-specific roles and regulatory mechanisms of 
lncRNAs [43].
The prognostic value of HOTAIR that we observed 
in 3 independent datasets further supports the reported 
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clinical value of HOTAIR in glioma [16]. Critically, 
this is the first study establishing a prognostic value 
for HOTAIR in lower grade glioma (grades II and III). 
Importantly, we also found that HOTAIR expression 
was able to identify a subset of GBM patients with poor 
prognosis even in the universe of HOXA9-negative GBM 
patients, indicating that the combinatorial evaluation 
of HOTAIR and HOXA9 expression levels may prove 
advantageous towards a molecularly-based stratification 
of GBM patients. Testing how the concomitant inhibition 
of HOTAIR and HOXA9 may affect the behavior of 
GBM in vitro and in vivo will be interesting and warrants 
further investigation in future studies. Furthermore, the 
clinical importance of HOTAIR suggests it as a putative 
therapeutic target. While drugs directly interfering 
with HOTAIR function are currently being studied 
[44–47] but still not clinically used in glioma, it may be 
interesting to test pharmacological approaches that act 
upstream of HOTAIR activation, namely PI3K inhibitors 
(e.g., PI-103 [48] and LY294002 [49]) that have been 
shown to silence HOXA9 transcription, and might thus 
result in HOTAIR downregulation. In addition, part 
of HOTAIR effects in glioma may also be limited by 
using drugs directed to PRC2 components, as the EZH2 
inhibitor DZNep [50], or drugs that specifically target 
LSD1 activity and have been tested in cancer [51, 52].
In summary, our study shows that (i) HOTAIR 
is highly expressed in a subset of malignant gliomas, 
independently of gene copy number alterations; (ii) 
epigenetic marks at the level of DNA methylation in 
particular CpG sites associate with HOTAIR levels 
in GBM; (iii) co-expression of HOTAIR and HOXA9 
occurs frequently in high-grade glioma, but not in other 
cancer types; (iv) HOTAIR is prognostically valuable in 
malignant glioma patients; and (v) HOTAIR and HOXA9 
may be useful biomarkers to integrate a molecularly-
based stratification of GBM patients. We anticipate that 
HOTAIR may mediate some of the effector mechanisms 
by which HOXA9 creates a more aggressive and therapy-
resistant form of GBM. Further studies are warranted 
to better identify HOTAIR downstream target genes at 
the genome-wide level in GBM, in an attempt to better 
understand the mechanisms by which HOTAIR affects 
survival of patients, and ultimately investigate new 
therapeutic opportunities.
MATERIALS AND METHODS
Glioma primary samples and cell lines
Glioma tumor specimens were obtained from 
“Hospital Braga” (n = 34) and “Hospitais da Universidade 
de Coimbra” (n = 39), Portugal, and from the Clermont-
Ferrand University Hospital Center (n = 51), France 
(Supplementary Table 1), upon approval by each Hospital’s 
ethical committee and patients signed a written individual 
informed consent according to institutional guidelines. 
Tumor tissues were snap-frozen in dry ice or isopentane 
cooled in liquid nitrogen directly from the operating room, 
and stored at –80° C. In the French dataset, 57% of the 
samples were IDH1 genotyped by EpigenDx (Worcester, 
MA) using pyrosequencing (assays ADS1703 and 
ADS1704), while the other 43% by analyzing the most 
frequent IDH1 mutations in exon 4 (codon 132) using 
RFLP [53]. Regarding 1p19q samples characterization, 
the analysis was performed using the Vysis 1p36/1q25 
and 19q13/19p13 FISH probe kit (4N6020, Abbott), 
according to manufacturer’s instructions. For some 
cases lacking 1p19q characterization, internexin A 
(INA) immunohistochemical analyses were carried out 
on paraffin sections using antibodies directed against 
internexin neuronal intermediate filament protein 
alpha (INA). Since INA expression was reported to 
be a surrogate marker of 1p19q codeletion [54, 55]), 
its expression was assessed to indirectly inquire about 
the 1p19q deletion status. Pediatric glioma cell lines 
KNS42, Res259, Res186, SF188, and UW479 were 
cultured in DMEM/F12 (Gibco, Grand Island, NY, USA) 
supplemented with 10% Fetal Bovine Serum (FBS; 
Biochrom, Berlin, DE), and 1% Penicillin-Streptomycin 
(Pen-Strep; Invitrogen, Grand Island, NY, USA) as 
previously described [56]. Commercially-available adult 
glioma cell lines A172, GAMG, SNB19, SW1783, U251, 
and U87MG were originally purchased from ATCC 
(Rockville, MD, USA), and the primary GBM-derived 
culture GBM-L18 (established in our lab) were cultured 
in DMEM (Gibco, Grand Island, NY, USA) supplemented 
with 10% FBS, and 1% Pen-Strep. U87MG (which do 
not express HOXA9 endogenously) were previously 
[28] genetically-engineered with murine stem cell virus 
(MSCV) retroviral vectors containing the HOXA9 coding 
region to obtain HOXA9 overexpressing cells (U87MG-
HOXA9) or with control empty vector (U87MG-MSCV). 
Selection of retrovirally-infected cells was maintained 
with 500 μg/mL G418 (Sigma-Aldrich, St. Louis, 
MO, USA). Incubations were performed at 37° C, in a 
humidified atmosphere containing 5% CO2.
TCGA data meta-analysis in glioma patients
HOTAIR gene expression, copy number, DNA 
methylation and clinical data were downloaded from 
TCGA; available from: http://cancergenome.nih.gov/, 
accessed 2017) [57]. 
TCGA Agilent’s G4502A 244K gene expression 
profiles from 572 GBMs, 27 grades II and III gliomas 
(Supplementary Table 1), and 10 unmatched normal 
samples were analyzed, and “level 3” values of HOTAIR 
(probe A_32_P168442) and HOXA9 (probe A_23_
P500998) were used. HOTAIR-high was considered when 
“level 3” value ≥0, and HOXA9-high when ≥2. RNA-
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seq data from additional 161 GBMs, 511 grades II and 
III glioma patients and 5 unmatched normal samples 
were also collected (Supplementary Table 1). These data 
were evaluated using Illumina HiSeq 2000 sequencing 
system. Genes with a “level 3” value = 0 were considered 
to have undetectable levels of mRNA expression. Cases 
were classified based on WHO malignancy grade and 
considering genetic information according to latest WHO 
recommendations [1] to: IDH-wt; IDH-mut (without 
1p/19q codeletion), and IDH-mut and 1p/19q codeleted.
Gene copy number data were assessed by Affymetrix 
Genome-Wide Human SNP Array 6.0 in 372 GBM 
samples. Gene amplifications or deletions were considered 
for Log2 copy number tumor/normal ≥0.5 (gene copy 
number ≥3) or ≤–0.5 (gene copy number ≤1), respectively.
Tumor DNA methylation profiles were detected by 
Illumina Infinium Human DNA Methylation 450 array and 
include the methylation status of 74 GBM samples. We 
evaluated 56 probes that span from the HOXC12 (upstream 
of HOTAIR) to HOXC11 (downstream of HOTAIR). High 
methylation was considered for β-values  > 0.5.
Analysis of HOTAIR expression in Oncomine 
and REMBRANDT
The human cancer microarray database Oncomine 
(www.oncomine.com; Oncomine™, Compendia Bioscience, 
Ann Arbor, MI) was used for analysis and visualization 
[58] of HOTAIR expression (probe 239153_at) in 45 WHO 
grade II, 98 WHO grade III, and 296 primary WHO grade 
IV gliomas (Supplementary Table 1). Categorization of 
HOTAIR-positive and HOTAIR-negative glioma patients 
was based on the Log2 median-centered intensity values 
of HOTAIR probe. Log2 median-centered intensity values 
>0 correspond to high HOTAIR expression, and Log2 
values ≤0 correspond to low/negative HOTAIR expression. 
The Oncomine database was also used to identify genes 
frequently co-expressed with HOTAIR in gliomas and other 
cancer datasets [lung (n = 167), breast (n = 593), leukemia 
(n = 197), and colorectal cancer (n = 237)]. Details on the 
normalization techniques and statistical calculations can be 
found on the website (www.oncomine.com) [58].
The REMBRANDT platform (National Cancer 
Institute REMBRANDT, accessed 2013 June; available 
now at https://gdoc.georgetown.edu/gdoc/) was queried to 
evaluate 67 GBM patients (Supplementary Table 1); the 
cut-off for HOTAIR high expression was established as 
≥4-fold than HOTAIR expression in non-tumor samples.
RNA extraction, cDNA synthesis, and gene 
expression analyses in primary glioma samples 
and cell lines
Total RNA was extracted from glioma patient 
samples and cell lines using the TRIzol method 
(Invitrogen, Carlsbad, CA, USA) for the Portuguese 
dataset or the RNeasy Mini Kit (Qiagen, Hamburg, 
GmbH) for the French dataset, and cDNA was synthesized 
using High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s protocol. 
For the Portuguese dataset, gene expression 
levels were assessed by RT-PCR (AmpliTaq Gold 
360, Applied Biosystems, Foster City, CA, USA) and 
quantitative reverse transcriptase real-time PCR (qPCR; 
KAPA Biosystems, Foster City, CA, USA) according 
to manufacturer’s instructions (primer sequences in 
Supplementary Table 7). Housekeeping genes used to 
normalize gene expression levels were hGUS, TBP, 
HPRT1, or ACTIN, as stated on each analysis. For all 
tested genes, the standard PCR parameters were as 
follows: 4 minutes at 94° C, 35 cycles of denaturation for 
30 seconds for the RT-PCR or 3 seconds for the qPCR at 
94° C, annealing for 30 seconds (Supplementary Table 7), 
extension at 72° C for 30 seconds, and final extension at 
72° C for 8 minutes for conventional PCR, or increments 
of 1° C each 5 seconds from 65 to 95° C for the qPCR. 
The cut-off for high expression of both HOTAIR and 
HOXA9 was established as >5% of relative expression 
(upon normalization to housekeeping gene).
In the French dataset, microfluidic-based 
quantitative analysis (Fuidigm) was used to assess 
HOTAIR and HOXA9 genes expression levels. cDNA 
was preamplified for 14 cycles with the pool of primers 
available in Supplementary Table 7 by using the TaqMan 
PreAmplification Master Mix (Applied Biosystems). 
qRT-PCRs were next conducted and validated on 
Fluidigm 96.96 Dynamic Arrays using the Biomark HD 
system (Fluidigm Corp.) according to the manufacturer’s 
instructions. The relative quantification in gene expression 
was determined after normalization to a geometrical mean 
of housekeeping genes expression, namely PPIA, HPRT1 
and TBP. For each condition, data presented in this study 
are obtained from two independent experiments, each 
analyzed in duplicate.
5-Aza-2′-deoxycytidine treatment, DNA isolation, 
bisulfite conversion and HOTAIR methylation-
specific PCR
Glioma cell lines were treated with 5 µM 5-Aza 
(Sigma-Aldrich®, St. Louis, MO, USA) or dimethyl 
sulfoxide (DMSO; Sigma-Aldrich®, St. Louis, MO, USA) 
for 72 hours with daily renewal. Cells were collected by 
trypsinization, and DNA and RNA were extracted by 
the TRIzol method. RNA was used to assess HOTAIR 
expression levels as previously described, and DNA was 
subjected to sodium bisulfite conversion using the EZ 
DNA Methylation-Gold™ Kit (Zymo Research, Foster 
City, CA, USA), according to the manufacturer’s protocol. 
Touchdown MSPs for HOTAIR promoter were performed 
(AmpliTaq Gold 360; 3 cycles at 62° C with decrement of 
1° C; 6 cycles at 59.5° C with decrement of 0.5° C; and 
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29 cycles at 57° C; primers in Supplementary Table 7). 
Blood DNA of a control subject (NB569) was bisulfite 
treated and used as an unmethylated control for MSP 
reactions. The same DNA was in vitro methylated (CpG 
Methyltransferase M.SssI; New England Biolabs Inc.) 
according to manufacturer’s protocol, followed by sodium 
bisulfite treatment, and used as a methylated control.
In the French dataset, HOTAIR DNA methylation 
profile was obtained by Illumina Infinium Human DNA 
Methylation 450 array performed on the 43 glioma 
samples. We evaluated 26 probes that cover the HOTAIR 
locus between HOXC11 and HOXC12 (chr12:54,355,686–
54,369,516). High methylation was considered for 
β-values  > 0.5.
In silico analysis of transcription factor binding 
sites in HOTAIR promoter by Genomatix
MatInspector from Genomatix software [59] 
(www.genomatix.de) was used to investigate putative 
transcription factors binding sites in HOTAIR gene. This 
in silico tool identifies transcription factor binding sites 
in nucleotide sequences based in a large library of weight 
matrices [59, 60]. A perfect match gets a matrix similarity 
of 1 when the tested sequence corresponds to the most 
conserved nucleotide at each position of the matrix. A 
good match to the matrix was considered when matrix 
similarity >0.80.
Chromatin-immunoprecipitation analysis
ChIP experiments were done as previously 
described [61]. In brief, U251, U87MG-MSCV and 
U87MG-HOXA9 cells were cross-linked with 1.42% 
formaldehyde for 15 minutes, followed by quenching with 
125 mM glycine for 5 minutes. Cells were then lysed with 
immunoprecipitation buffer (150 mM NaCl, 50 mM Tris-
HCl, 5 mM EDTA, 0.5% NP-40, 1% Triton X-100) and 
chromatin was sheared by sonication (Sonics Vibra Cell 
VC70T, 21 cycles for 15 seconds) to obtain DNA fragments 
of approximately 0.5–1kb. The volume of sheared 
chromatin equivalent to 2 million cells was incubated 
with the required antibody in an ultrasonic bath for 15 
minutes, followed by incubation with protein A-sepharose 
beads (Amersham, Uppsala, SE) and Chelex 100 (Bio-
Rad, Hercules, CA, USA). The following antibodies were 
used per immunoprecipitation: 4 μg anti-HOXA9 (Santa 
Cruz Biotechnologies, Santa Cruz, CA), and 3 μg anti-
Immunoglobulin G (IgG; Sigma-Aldrich, St. Louis, MO, 
USA) as ChIP negative control. The input represents a 
control for the amount of DNA used in precipitations. 
DNA amplification was done by qPCR (KAPA SYBR 
FAST, KAPA Biosystems) according to manufacturer’s 
instructions with primers designed to amplify a portion 
of the HOTAIR promoter region that spans from bp 
-991 to -826 from the HOTAIR transcriptional start site 
(Supplementary Table 7). The qPCR parameters were as 
follows: 4 minutes at 94° C, 35 cycles of denaturation for 
3 seconds, annealing for 30 seconds at 60° C, extension 
at 72° C for 30 seconds, and final extension consisting 
in increments of 1° C each 5 seconds from 65 to 95° C. 
The U251 fold enrichment of HOTAIR promoter over IgG, 
and the fold change occupancy of HOTAIR promoter in 
HOXA9-overexpressing over their negative counterparts 
for U87MG, were calculated for each experiment 
using the ΔΔCt method as described previously [62]. 
Three biological replicates were tested, and each qPCR 
experiment was performed in triplicates.
Statistical analyses
Statistical analyses were performed using the SPSS 
22.0 software (SPSS, Inc., Chicago, IL, USA) for the 
TCGA and Portuguese datasets, and the Stata software, 
version 13 (StataCorp, College Station, TX, US) for the 
French dataset. Tests were two-sided, with a type I error 
set at α = 0.05. Due to more limited sample size in the 
French dataset, HOTAIR threshold has been determined 
according to ROC curve analysis, and estimation of 
several indexes recommended in literature [63–65] and 
biological relevance. Univariable survival analyses 
to assess the prognostic value of HOTAIR and of other 
clinicopathological features (patient age, gender, KPS, 
use of chemoradiation therapy, and institution where the 
patients were treated) were performed by the Log-rank 
test whenever these data were available. Additionally, 
the independent prognostic value of HOTAIR was further 
analyzed by a multivariable Cox proportional hazard 
model adjusted for those potential confounding variables. 
The Chi-square test was used to assess differences 
between the distributions of tumors with high and low 
HOTAIR expression, stratified for methylation levels 
(β-value, TCGA). Correlation between the expression 
levels of HOTAIR and HOXA9 were calculated by 
Pearson’s or Spearman’s correlation as indicated 
throughout the text, and according to data normality. 
HOTAIR expression level differences between histological 
groups was assessed by one-way ANOVA (Kruskal-
Wallis test) for the TCGA dataset. The qPCR differences 
in ChIP experiments and between histological groups in 
the French dataset, and genes expression were calculated 
by Mann-Whitney test and unpaired Student’s t-test, 
respectively, using Prism GraphPad software (version 
6.0a, San Diego, CA, USA). In Oncomine [58], each gene 
was evaluated for differential expression using Student’s 
t-test in the case of two-class analyses (e.g. tumor tissue 
versus respective normal tissue); for multiclass analyses 
(e.g. grade II, III, and IV gliomas) Pearson’s correlation 
was used. The association between methylation indexes 
of HOTAIR and its expression levels in the TCGA dataset 
was measured by the Pearson’s correlation (r) using SPSS 
22.0 software. 
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